You just read:

Nordic Nanovector Highlights Promising Clinical Results from Phase 1/2 Trial of Betalutin® in Relapsed/Refractory Indolent non-Hodgkin's Lymphoma

News provided by

Nordic Nanovector

01 Nov, 2018, 13:35 GMT